会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明申请
    • THE USE OF ANTIBODIES TO TNF OR FRAGMENTS DERIVED THEREOF AND XANTHINE DERIVATIVES FOR COMBINATION THERAPY AND COMPOSITIONS THEREFOR
    • 抗体对TNF或其衍生物的片段的使用和用于组合治疗的Xanthine衍生物及其组合物
    • WO1992007585A1
    • 1992-05-14
    • PCT/GB1991001907
    • 1991-10-30
    • CELLTECH LIMITEDHOECHST AKTIENGESELLSCHAFTANAGNOSTOPULOS, HiristoGEBERT, UlrichHANEL, HeinzLIMBERT, MichaelBODMER, Mark, WilliamHIGGS, Gerald, Anthony
    • CELLTECH LIMITEDHOECHST AKTIENGESELLSCHAFT
    • A61K39/395
    • A61K39/395A61K31/52A61K2300/00
    • A combined preparation for simultaneous combined, simultaneous separate, or sequential use in the therapy or prophylaxis of disorders associated with undesirably high levels of TNF, e.g. septic or endotoxic shock and immunoregulatory and inflammatory disorders, which comprises an antibody to TNF or a TNF binding fragment thereof and a xanthine derivative. Particular preferred xanthine derivatives are 3,7-dimethyl-1-(5-oxo-hexyl)xanthine (known as Pentoxifylline or Trental) and 1-(5-hydroxy-5-methylhexyl)-3-methylxanthine and similar compounds. The anti-TNF antibody or fragment is preferably monospecific especially a humanised recombinant antibody or fragment. The ratio of xanthine derivative to anti-TNF antibody component used may be in the range between 450:1 and 1:10 and doses of anti-TNF component in the range 0.001-30mg/kg/day and doses of xanthine derivative in the range 0.5 to 100mg/kg/day may be administered during treatment of human or animal subjects. It has been found that when an anti-TNF antibody and a xanthine derivative are used together in some experimental models of septic shock, a surprising combination effect is observed.
    • 用于同时组合,同时分开或顺序使用的联合制剂,用于治疗或预防与不期望的高水平的TNF相关的病症,例如, 脓毒性或内毒素性休克和免疫调节性和炎症性疾病,其包含TNF抗体或其TNF结合片段和黄嘌呤衍生物。 特别优选的黄嘌呤衍生物是3,7-二甲基-1-(5-氧代 - 己基)黄嘌呤(称为己酮可可碱或特伦塔尔)和1-(5-羟基-5-甲基己基)-3-甲基黄嘌呤和类似化合物。 抗TNF抗体或片段优选是单特异性的,特别是人源化的重组抗体或片段。 黄嘌呤衍生物与抗TNF抗体组分的比例可以在450:1至1:10的范围内,抗TNF成分的剂量范围为0.001-30mg / kg /天,黄嘌呤衍生物的剂量范围为 在人或动物受试者的治疗期间可以施用0.5至100mg / kg /天。 已经发现,当在一些感染性休克的实验模型中一起使用抗TNF抗体和黄嘌呤衍生物时,观察到惊人的组合效应。